Brind.

Genmab Grants Stock Units and Warrants to Employees

1 report, 1 independent Updated Sep 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Genmab's Board of Directors granted 13,794 restricted stock units and 13,331 warrants to employees and subsidiaries on September 1, 2026. The restricted stock units are conditional rights to receive shares, while the warrants entitle owners to subscribe to shares upon paying an exercise price of DKK 2,268.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The grant impacts Genmab's equity base and future capital structure. The restricted stock units are valued at DKK 2,268 per share, and the warrants have a calculated fair value of DKK 781.96 per warrant.

From manilatimes.net

Who's involved

  • GenmabDanish biotechnology company that granted the stock units and warrants

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • GenmabSpeculative

    The grant of restricted stock units and warrants could impact the company's equity base and future capital structure.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped